Navigation Links
Compound might defeat African sleeping sickness, clinical trial beginning this month

One of the most devastating diseases in sub-Saharan Africa almost disappeared in the late 1950s. That disease, African sleeping sickness, or trypanosomiasis, largely succumbed to heroic public health efforts -- including relocating entire villages. But in the past several decades, because of post-colonial turmoil, the catastrophic illness has come back to ravage parts of Angola, the Democratic Republic of the Congo, the Sudan and other countries. In some regions, the tsetse fly-borne infection rivals or exceeds the toll AIDS takes.

Trypanosomiasis is passed from human to human by tsetse fly bites. It produces fever, lymph nodes inflammation, eventual impairment of the brain and nervous system in its late stage and, if not treated, death. The World Health Organization has estimated that more then 300,000 people are infected, and more than 60 million living in the region are at risk.

Now, real hope for a better treatment is on the horizon, based on research conducted in part at the University of North Carolina at Chapel Hill. In Phase II clinical trials, a new oral drug, DB289, demonstrated safety and high effectiveness in subjects with the early stage of sleeping sickness. Scientists are launching a Phase III trial this summer involving for the first time hundreds of patients who will be treated with the drug.

The Bill & Melinda Gates Foundation is supporting the work, which is being led by Dr. Richard R. Tidwell, professor of pathology and laboratory medicine at the UNC School of Medicine.

"This is very exciting time for us and the international consortium we pulled together to develop the first drug made to specifically combat this terrible re-emerging disease," Tidwell said. "The compound DB289 will be the first new drug for early stage (blood stage) African sleeping sickness in 50 years, and the only oral drug that's ever been specifically developed for it."

Oral administration is important for treating the disease which
'"/>

Source:University of North Carolina at Chapel Hill


Page: 1 2 3 4

Related biology news :

1. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
2. Newly Discovered Compound Blocks Known Cancer-Causing Protein
3. Compounds in plastic packaging act as environmental estrogens altering breast genes
4. Compound from Chinese medicine shows promise in head and neck cancer
5. Anti-cancer Compound In Beer Gaining Interest
6. Compound from marine bacteria shows potential as multiple myeloma therapy
7. Compound in dairy products targets diabetes
8. Compound eyes, evolutionary ties
9. Antibiotic might fight HIV-induced neurological problems
10. Newly discovered pathway might help in design of cancer drugs
11. Stem cells electric abilities might help their safe clinical use
Post Your Comments:
(Date:5/16/2008)... Delays and denials of shipments involving regula...ustry are of growing concern to safety and industr...rkshop, they agreed on an action plan for the Medi...hospitals, research centres and organizations that...ources. , The shipment issues have surfaced over...
(Date:5/16/2008)... BIRMINGHAM, Ala. A new study reveals the geneti...the version responsible for sexual transmission, i...mportant clues in the ongoing search for an effect...ersity of Alabama at Birmingham (UAB). The UAB tea... few lead to sexual transmission. , Earlier stud...
(Date:5/16/2008)... Cancer, nervous system disorders such as Parkins...have one thing in common: Both in afflicted tissue...ative changes in important biomolecules. These are...e notorious free radicals that are formed as a by-...r proteins, nucleic and fatty acids. , Today, re...
(Date:5/16/2008)... A world-renowned team of experts in biomechanics...essor Hugh Herr of the Massachusetts Institute of ...at the prostheses worn by Oscar Pistorius, a 21-ye...te, provide him with an unfair advantage in the 40... collected at the Rice University Locomotion Labor...
Breaking Biology News(10 mins):Experts tackle shipment issues for beneficial radiation sources 2Experts tackle shipment issues for beneficial radiation sources 3HIV infection stems from few viruses 2Biosensor for measuring stress in cells 2Breaking news: Study revives Olympic prospects for amputee sprinter 2Breaking news: Study revives Olympic prospects for amputee sprinter 3Chinas biotech industry 3A An Asian dragon is growing 9197 1Chinas biotech industry 3A An Asian dragon is growing 9197 2Chinas biotech industry 3A An Asian dragon is growing 9197 3Chinas biotech industry 3A An Asian dragon is growing 9197 4Chinas biotech industry 3A An Asian dragon is growing 9197 5Chinas biotech industry 3A An Asian dragon is growing 9197 6Chinas biotech industry 3A An Asian dragon is growing 9197 74 health behaviors can add 14 extra years of life 1799 14 health behaviors can add 14 extra years of life 1799 2Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG 28Hamburg Germany 29 9192 1Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG 28Hamburg Germany 29 9192 2Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference 2492 1
...at the University of Virginia Health System have s...ous RNA (ribonucleic acid) in muscle cells can rev...uscular dystrophy in adults. , About 40,000 peopl...rophy (MMD). The disease can cause a slow, progres...cataracts and insulin resistance. Many people don,...
...ronic device designed to "zap" away migraine pain ...r millions of people who suffer from the debilitat...experimental device appears to be effective in eli... onset of the migraine. , The study, led by the ...estigators, was presented Thursday (6/22) at the a...
...e of the newest and most powerful tools of biomedi... Galveston (UTMB) researchers have scored a dramat.... , The scientists were the first to use what are ...ead of human colorectal cancer cells implanted in ...first described in 2001, are tiny bits of genetic ...
... the parasite that causes African sleeping sicknes...reviously unknown way of making fatty acids, a com...e find unveils more about the biology of this hard...esigning new drugs to fight the illness that infec...orldwide. , Results of the study, in the Aug. 25 ...
Other Biology News:Toxic molecule may cause most common type of muscular dystrophy 2Device effective in zapping the pain out of migraines 2RNA interference stops colon cancer spread in mice 2African parasite makes component of fat differently from all other organisms 2African parasite makes component of fat differently from all other organisms 3
(Date:5/16/2008)....J., May 16 /- Senesco,Tech... SNT ) today reported,financial results for the t...he three month period ended March 31, 2008 was $2.... loss of $0.8 million, or,$0.05 per share, for the...rease in net loss was primarily the result of an i...
(Date:5/16/2008)...land, May 16 /- Arpida Ltd....d Drug Administration,(FDA) has accepted for revie...claprim in the treatment of complicated Skin and S... the submission of the NDA to,the agency in March ... to,the iclaprim NDA and has established the Presc...
(Date:5/15/2008)...earchers at UC Davis have shown that they can use ...nt, an atomic force microscope. , "It turns arou...o calibrate an instrument," said Volkmar Heinrich,...al Engineering at UC Davis and co-author of the pa...atomic force microscope uses a tiny lever that run...
(Date:5/15/2008)...., May 15 /- NeurogesX, Inc...cused on developing novel,pain management therapie...,on Monday, May 19, 2008 at the Rodman & Renshaw 5...Tonno, President and Chief Executive,Officer, will...ial Officer,will be available to respond to quest...
Breaking Biology Technology:Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 2Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 3Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 4Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 5Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 6Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 7Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results 8Arpida Announces FDA Acceptance of the Iclaprim New Drug Application 2Arpida Announces FDA Acceptance of the Iclaprim New Drug Application 3NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 3
... , , Multiporator , , , ,... Transfection Protocol , Protocol No. ..., , , , , , , , ...21, EBV transfected B cell line, MHC class I A, ,...ss II positive, , , ...
... , , Multiporator / Electroporator 2510 ... , Transformation Protocol ,... , , , , , , ,...oorganism , Ustilago maydis fbd11, prot...ype , Phytopathogenic fungus, yeast-lik...
... , , Multiporator / Electroporator 2510 ... , Transformation Protocol ,... , , , , , , ,...oorganism , Staphylococcus epidermidis,... Bacteria, gram positive, , ...
... , , Multiporator / Electroporator 2510 ... , Transformation Protocol , ... , , , , , , , ...rganism , Pseudomonas aeruginosa, ... Bacteria, gram negative, , ,...
Other Biology Technology:721.221 2Ustilago maydis 2Ustilago maydis 3Staphylococcus epidermidis 2Pseudomonas aeruginosa 2
Piperazine-N',N'-bis(2-ethanesulfonic acid), monosodium salt
Determin interaction of your protein with Echelons lipids
Identify and characterize Phosphoinositide (PI(4,5)P2) binding
...with motorized heated lid and skirted inner lid ha...d chips. The four screw-down points allow attachme...of the motorized lid is set with software and is a...interchangeable Moto Alpha unit functions on any D...
Biology Products: